Usually, a decrease in VEGF in intraocular fluids due to intravitreal anti‐VEGF therapy leads to a reduction in CT, for example in patients with diabetic retinopathy (Kniggendorf et al. 2016). The gene discussed is VEGFA; the disease is diabetic retinopathy.